CAGRISEMA BLEND 10mg (Cagrilintide 5mg/Semaglutide 5mg) For Weight Loss

Carglisema (cargliptin/semaglutide) is a combination of cargliptin, a dual agonist of starch and calcitonin receptors, and semaglutide, a GLP-1 agonist. It is an effective long-term combination therapy for the treatment of type 2 diabetes and obesity.

Results from clinical trials of Cagrisema have shown that it exhibits superior results in weight loss and blood glucose reduction compared to cagliptin or semaglutide alone. In addition, Cagrisema significantly reduced patients' glycated hemoglobin (HbA1c) levels.

There are many peptide-based weight loss products on the market today, and HBY can offer these products and accept customizations as well:

How does Cagrisema work?

Cagrisema is a novel dual-action therapy designed to effectively treat type 2 diabetes and obesity by combining semaglutide and cagrilintide, two complementary pharmaceutical ingredients.

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the action of the natural gut hormone GLP-1, slowing digestion, enhancing satiety, and lowering blood sugar by increasing glucose-dependent insulin secretion. Cagliflozin peptide is a long-acting amyloid peptide analog with dual agonism that acts on amyloid peptide and calcitonin receptors, mimicking the effects of the amyloid peptide to further promote satiety and reduce intestinal sensitivity. Sugar absorption. Therefore, it may enhance the weight loss effects of Semaglutide.

Carglisema is unique in that it combines the strengths of both Semarutide and Cargliptin peptides to form a powerful combination therapy. Semaglutide starts with blood sugar control, reducing sugar intake and absorption. Cagliptin starts by regulating appetite, reducing food intake, and increasing energy expenditure. This two-pronged mechanism allows Cagliflozin to provide a more comprehensive treatment for patients with type 2 diabetes and obesity.

3. What are the potential benefits of Cagrisema?

Effective in controlling blood glucose: Cagrisema has shown significant efficacy in lowering blood glucose levels in clinical trials. the Trifecta trial demonstrated that Cagrisema significantly lowered HbA1c levels by 1.8% compared to placebo, and in the DURATION-6 trial, Cagrisema lowered HbA1c by 1.7% compared to dulaglutide. This shows that Carglisema significantly reduces HbA1c levels, which is a key indicator of long-term glycemic control.

Significant weight loss: The dual mechanism of action of Carglisema reduces body weight by decreasing appetite and increasing satiety and energy expenditure. In the STEP obesity trial, carglima resulted in an average weight loss of 12.1% compared to placebo and significantly improved cardiometabolic markers. In the RESET-O trial, carglisema resulted in an average weight loss of 16.4% and significant reductions in body fat percentage and waist circumference compared to placebo.

Improved Cardiovascular Health: The positive effects of carglisema on glycemic and weight control may also translate into improved cardiovascular health. Studies have shown that Cargresema lowers blood pressure, improves blood lipids, and reduces the risk of cardiovascular events.
 

Product Images:

Shipping:

3rd Lab report: